EFA
PRAX icon

Englebert Financial Advisers’s Praxis Precision Medicines PRAX Stock Holding History

Englebert Financial Advisers’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Buy
1,306
+517
+66% +$164K 0.43% 44
2026
Q1 		$254K Buy
+789
New +$244K 0.29% 49

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Englebert Financial Advisers's PRAX Position: Q2 2026 in Review

Englebert Financial Advisers increased its Praxis Precision Medicines (PRAX) stake by 66% in Q2 2026, buying an estimated $164K and bringing the position to 1,306 shares worth $437K. The position accounts for 0.43% of the portfolio, ranked #44.

Englebert Financial Advisers first reported a position in PRAX in Q1 2026 and has held it in 2 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Englebert Financial Advisers held 1,306 shares of Praxis Precision Medicines worth $437K as of Q2 2026.
  • Englebert Financial Advisers bought 517 Praxis Precision Medicines shares in Q2 2026, an estimated $164K.
  • Praxis Precision Medicines made up 0.43% of Englebert Financial Advisers's portfolio in Q2 2026, its #44 holding.
  • Englebert Financial Advisers first reported a position in Praxis Precision Medicines in Q1 2026 and has held it in 2 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Englebert Financial Advisers's 13F filing for Q2 2026, filed 22 Jul 2026.